Ege University Experience in Cardiac Transplantation

Basit Öğe Kaydı
dc.contributor.authorOzbaran, M.
dc.contributor.authorYagdi, T.
dc.contributor.authorEngin, C.
dc.contributor.authorNalbantgil, S.
dc.contributor.authorAyik, F.
dc.contributor.authorOguz, E.
dc.contributor.authorZoghi, M.
dc.date.accessioned2019-10-27T21:24:32Z
dc.date.available2019-10-27T21:24:32Z
dc.date.issued2011
dc.departmentEge Üniversitesien_US
dc.description22nd Congress of the Spanish-Liver-Transplantation-Society (SETH) -- OCT 29-30, 2010 -- Madrid, SPAINen_US
dc.description.abstractBackground. End-stage heart failure can result from many cardiac and noncardiac entities that produce a poor prognosis. Medical and interventional modalities are widely used to treat this condition, although the ultimate therapy remains heart transplantation. Herein we present our clinical experience with 140 patients who underwent orthotopic heart transplantation. Methods. Between February 1998 and September 2010, we transplanted 140 patients with a mean age of 40 +/- 13 years, including 109 men (77.8%) and 31 women (22%). There were 101 patients (73%) with dilated cardiomyopathy and 39 (27%) with ischemic cardiomyopathy. Two patients were retransplanted owing to graft failure. Sixteen patients on assist device support were successfully bridged to transplantation. Results. Eighteen patients (12.8%) died within 30 days with the most common causes being right ventricular failure (8/18, 44%) and infection (4/18, 22%). Overall mortality of 39% (55/140) was most commonly caused by infection (29%, 16/55) or right ventricular failure (20%, 11/55). Nine patients (16%) died suddenly outside of the hospital. Three patients died of rejection; 4 of graft failure, and 4 of malignant disease. Conclusions. Heart transplantation remains the standard treatment modality for end-stage cardiac failure. But significant waiting list mortality rates are due to the worldwide shortage of donors. Heart transplantation in Turkey is feasible for a small and strictly selected number of patients with nonreversible congestive heart failure. In recent years, ventricular assist device applications have successful bridged subjects to transplantation, saving many patients on active waiting lists.en_US
dc.description.sponsorshipSpanish Liver Transplantation Socen_US
dc.identifier.doi10.1016/j.transproceed.2011.01.108en_US
dc.identifier.endpage941en_US
dc.identifier.issn0041-1345
dc.identifier.issue3en_US
dc.identifier.pmid21486633en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage938en_US
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2011.01.108
dc.identifier.urihttps://hdl.handle.net/11454/44577
dc.identifier.volume43en_US
dc.identifier.wosWOS:000289860300063en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofTransplantation Proceedingsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleEge University Experience in Cardiac Transplantationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu